Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1984-9-5
|
pubmed:abstractText |
HBs Ag carrier rate among pregnant women is 1.5% in our hospital near Paris, six times higher than French national prevalence among women. 78% of them are of extra-metropolitan origin (especially from the African continent), 80% have a low socioeconomic status. Their newborns are at risk of "mother-to-infant" transmission of the virus HB. The risks, mechanisms and consequences of such a transmission are studied. For these reasons, it seems reasonable to perform routine prenatal testing for HBs Ag carriage. We have successively carried out two prophylactic methods. From June 1980 to October 1982, prevention with specific immunoglobulins (HBIG) was used: ten infants received at birth 0.5 ml, and 0.1 ml/kg at 1, 2, 4, 6 months of age. At 6 months, they all were safe of liver damage, HBs Ag and HBe Ag negative. Eleven infants received only the first HBIG injection. From October 1982 to September 1983, fifteen carrier women were identified at the time of delivery, and all accepted the sero-vaccination procedure for the newborn: HBIG (1 ml) and vaccine before 48 hours of life and at one month, vaccine alone at two months. The babies were controlled (9 at 4 months, 3 at 12 months) and all were safe of liver damage, HBs Ag and HBe Ag negative, with HBs antibody mean value of 240 m I.U./ml. We are grateful to the collaboration of the Departments for Mother and Infant Protection in our region--according to the usual chronology of the visits--for these satisfactory performance and results of the sero-vaccination.
|
pubmed:language |
fre
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0338-4535
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
27
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
169-80
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:6463508-Carrier State,
pubmed-meshheading:6463508-Communicable Disease Control,
pubmed-meshheading:6463508-Female,
pubmed-meshheading:6463508-Hepatitis B,
pubmed-meshheading:6463508-Hepatitis B Surface Antigens,
pubmed-meshheading:6463508-Hepatitis B virus,
pubmed-meshheading:6463508-Humans,
pubmed-meshheading:6463508-Immunization,
pubmed-meshheading:6463508-Infant,
pubmed-meshheading:6463508-Infant, Newborn,
pubmed-meshheading:6463508-Pregnancy,
pubmed-meshheading:6463508-Socioeconomic Factors
|
pubmed:year |
1984
|
pubmed:articleTitle |
[Prevention of the vertical transmission of hepatitis B virus. Experience of the Perinatal Center of Hemobiology].
|
pubmed:publicationType |
Journal Article,
English Abstract
|